{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:38:58Z","timestamp":1790271538094,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01269-9","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T06:30:41Z","timestamp":1760596241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A replicating RNA vaccine protects against severe fever with thrombocytopenia syndrome virus infection in mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Allie","family":"Stamper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bisom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Meade-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanna","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Hinkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hawman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"1269_CR1","doi-asserted-by":"publisher","first-page":"e01069","DOI":"10.1128\/jvi.01069-24","volume":"98","author":"JH Kuhn","year":"2024","unstructured":"Kuhn, J. H. et al. Promotion of order Bunyavirales to class Bunyaviricetes to accommodate a rapidly increasing number of related polyploviricotine viruses. J. Virol. 98, e01069\u201324 (2024).","journal-title":"J. Virol."},{"key":"1269_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s12276-021-00610-1","volume":"53","author":"MA Casel","year":"2021","unstructured":"Casel, M. A., Park, S. J. & Choi, Y. K. Severe fever with thrombocytopenia syndrome virus: emerging novel phlebovirus and their control strategy. Exp. Mol. Med. 53, 713\u2013722 (2021).","journal-title":"Exp. Mol. Med."},{"key":"1269_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41541-020-00257-5","volume":"5","author":"NE Bopp","year":"2020","unstructured":"Bopp, N. E. et al. Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. npj Vaccines 5, 111 (2020).","journal-title":"npj Vaccines"},{"key":"1269_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.15585\/mmwr.mm6747a3","volume":"67","author":"CB Beard","year":"2018","unstructured":"Beard, C. B. et al. Multistate Infestation with the exotic disease-vector tick haemaphysalis longicornis - United States, August 2017-September 2018. Morb. Mortal. Wkly. Rep. 67, 1310\u20131313 (2018).","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"1269_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1203378","volume":"367","author":"LK McMullan","year":"2012","unstructured":"McMullan, L. K. et al. A new phlebovirus associated with severe febrile illness in Missouri. N. Engl. J. Med. 367, 834\u2013841 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1269_CR6","doi-asserted-by":"publisher","first-page":"e0004210","DOI":"10.1371\/journal.pntd.0004210","volume":"10","author":"JR Spengler","year":"2016","unstructured":"Spengler, J. R., Bergeron, \u00c9. & Rollin, P. E. Seroepidemiological studies of Crimean-Congo hemorrhagic fever virus in domestic and wild animals. PLoS Negl. Trop. Dis.10, e0004210 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1269_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1033946","volume":"13","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. Risk factors of severe fever with thrombocytopenia syndrome combined with central neurological complications: A five-year retrospective case\u2013control study. Front. Microbiol. 13, 1033946 (2022).","journal-title":"Front. Microbiol."},{"key":"1269_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fmicb.2020.00150","volume":"11","author":"M Takayama-Ito","year":"2020","unstructured":"Takayama-Ito, M. & Saijo, M. Antiviral drugs against severe fever with thrombocytopenia syndrome virus infection. Front. Microbiol. 11, 150 (2020).","journal-title":"Front. Microbiol."},{"key":"1269_CR9","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/v14081668","volume":"14","author":"H Fujii","year":"2022","unstructured":"Fujii, H. et al. Susceptibility of type I interferon receptor knock-out mice to heartland bandavirus (HRTV) infection and efficacy of favipiravir and ribavirin in the treatment of the mice infected with HRTV. Viruses 14, 1668 (2022).","journal-title":"Viruses"},{"key":"1269_CR10","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/cid\/cit530","volume":"57","author":"W Liu","year":"2013","unstructured":"Liu, W. et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in China who had severe fever with thrombocytopenia syndrome. Clin. Infect. Dis. 57, 1292\u20131299 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"1269_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/v16010128","volume":"16","author":"D Kim","year":"2024","unstructured":"Kim, D., Lai, C. J., Cha, I. & Jung, J. U. Current progress of severe fever with thrombocytopenia syndrome virus (SFTSV) vaccine development. Viruses 16, 128 (2024).","journal-title":"Viruses"},{"key":"1269_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51108-z","volume":"15","author":"X Ren","year":"2024","unstructured":"Ren, X. et al. A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection. Nat. Commun. 15, 7009 (2024).","journal-title":"Nat. Commun."},{"key":"1269_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom, K., Berg, F., van den. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117\u2013129 (2021).","journal-title":"Gene Ther."},{"key":"1269_CR14","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.ymthe.2023.06.017","volume":"31","author":"T Kimura","year":"2023","unstructured":"Kimura, T. et al. A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation. Mol. Ther. 31, 2360\u20132375 (2023).","journal-title":"Mol. Ther."},{"key":"1269_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102595","volume":"36","author":"T Kimura","year":"2025","unstructured":"Kimura, T. et al. Antigen-dependent interplay of formulation, systemic innate responses, and antibody responses to multi-component replicon RNA vaccination. Mol. Ther. Nucleic Acids 36, 102595 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1269_CR16","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","volume":"26","author":"JH Erasmus","year":"2018","unstructured":"Erasmus, J. H. et al. A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol. Ther. 26, 2507\u20132522 (2018).","journal-title":"Mol. Ther."},{"key":"1269_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc9396","volume":"12","author":"JH Erasmus","year":"2020","unstructured":"Erasmus, J. H. et al. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med.12, eabc9396 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1269_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41541-023-00799-4","volume":"9","author":"Z MacMillen","year":"2024","unstructured":"MacMillen, Z. et al. Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine. npj Vaccines9, 12 (2024).","journal-title":"npj Vaccines"},{"key":"1269_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi1625","volume":"16","author":"NL Warner","year":"2024","unstructured":"Warner, N. L. et al. A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models. Sci. Transl. Med.16, eadi1625 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1269_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41541-024-00887-z","volume":"9","author":"D Hawman","year":"2024","unstructured":"Hawman, D. et al. A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever. npj Vaccines 9, 86 (2024).","journal-title":"npj Vaccines"},{"key":"1269_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104188","volume":"82","author":"SS Leventhal","year":"2022","unstructured":"Leventhal, S. S. et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. eBioMedicine 82, 104188 (2022).","journal-title":"eBioMedicine"},{"key":"1269_CR22","unstructured":"HDT Bio\u2019s COVID-19 vaccine wins regulatory approval in India. Available from https:\/\/hdt.bio\/hdt-bios-covid-19-vaccine-wins-regulatory-approval-in-india\/ (2022)."},{"key":"1269_CR23","unstructured":"Bio H. HDT Bio partner Quratis doses first healthy volunteers in phase 1 trial of HDT Bio\u2019s RNA COVID-19 vaccine in South Korea. https:\/\/hdt.bio\/hdt-bio-partner-quratis-doses-first-healthy-volunteers-in-phase-1-trial-of-hdt-bios-rna-covid-19-vaccine-in-south-korea\/ (2021)."},{"key":"1269_CR24","unstructured":"Bio H. Brazil\u2019s SENAI CIMATEC doses first healthy volunteers in phase 1 trial of HDT Bio\u2019s RNA COVID-19 vaccine. https:\/\/hdt.bio\/brazils-senai-cimatec-doses-first-healthy-volunteers-in-phase-1-trial-of-hdt-bios-rna-covid-19-vaccine\/ (2022)."},{"key":"1269_CR25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/s41591-024-02955-2","volume":"30","author":"A Saraf","year":"2024","unstructured":"Saraf, A. et al. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial. Nat. Med. 30, 1363\u20131372 (2024).","journal-title":"Nat. Med."},{"key":"1269_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01076-2","volume":"10","author":"D Kumar","year":"2025","unstructured":"Kumar, D. et al. Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19. npj Vaccines 10, 42 (2025).","journal-title":"npj Vaccines"},{"key":"1269_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.797189","volume":"12","author":"J Sun","year":"2022","unstructured":"Sun, J. et al. Animal model of severe fever with thrombocytopenia syndrome virus infection. Front. Microbiol. 12, 797189 (2022).","journal-title":"Front. Microbiol."},{"key":"1269_CR28","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","volume":"198","author":"T Pepini","year":"2017","unstructured":"Pepini, T. et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol.198, 4012\u20134024 (2017).","journal-title":"J. Immunol."},{"key":"1269_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s42826-020-00070-0","volume":"36","author":"SC Park","year":"2020","unstructured":"Park, S. C. et al. Pathogenicity of severe fever with thrombocytopenia syndrome virus in mice regulated in type I interferon signaling: Severe fever with thrombocytopenia and type I interferon. Lab Anim. Res. 36, 38 (2020).","journal-title":"Lab Anim. Res."},{"key":"1269_CR30","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1073\/pnas.1120246109","volume":"109","author":"C Jin","year":"2012","unstructured":"Jin, C. et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57\/BL6 mouse model. Proc. Natl. Acad. Sci. USA 109, 10053\u201310058 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1269_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105017","volume":"101","author":"SS Leventhal","year":"2024","unstructured":"Leventhal, S. S. et al. Single dose, dual antigen RNA vaccines protect against lethal Crimean-Congo haemorrhagic fever virus infection in mice. eBioMedicine 101, 105017 (2024).","journal-title":"eBioMedicine"},{"key":"1269_CR32","unstructured":"Hawman, D. et al. Antibodies targeting the CCHFV nucleocapsid protein require TRIM21 for protection. https:\/\/app.readcube.com\/library\/4bb41255-7d58-4e66-8dbb-ea653383df34\/item\/c1d7ea7f-db3e-42f1-a2f3-5ff5681435ca (2024)."},{"key":"1269_CR33","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1128\/CVI.00222-13","volume":"20","author":"X Guo","year":"2013","unstructured":"Guo, X. et al. Human antibody neutralizes severe Fever with thrombocytopenia syndrome virus, an emerging hemorrhagic Fever virus. Clin. Vaccin. Immunol. 20, 1426\u20131432 (2013).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1269_CR34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2400163121","volume":"121","author":"Z Chang","year":"2024","unstructured":"Chang, Z. et al. Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model. Proc. Natl. Acad. Sci. USA 121, e2400163121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1269_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00771-2","volume":"8","author":"JY Kim","year":"2023","unstructured":"Kim, J. Y. et al. mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice. npj Vaccines 8, 167 (2023).","journal-title":"npj Vaccines"},{"key":"1269_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00769-24","volume":"98","author":"J Lu","year":"2024","unstructured":"Lu, J. et al. A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses. J. Virol. 98, e00769-24 (2024).","journal-title":"J. Virol."},{"key":"1269_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29203","volume":"95","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. SFTSV Gn-Head mRNA vaccine confers efficient protection against lethal viral challenge. J. Me\u0301d. Virol. 95, e29203 (2023).","journal-title":"J. Me\u0301d. Virol."},{"key":"1269_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41541-021-00293-9","volume":"6","author":"JJ Suschak","year":"2021","unstructured":"Suschak, J. J. et al. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. npj Vaccines 6, 31 (2021).","journal-title":"npj Vaccines"},{"key":"1269_CR39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","volume":"100","author":"DA Bente","year":"2013","unstructured":"Bente, D. A. et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir. Res. 100, 159\u2013189 (2013).","journal-title":"Antivir. Res."},{"key":"1269_CR40","doi-asserted-by":"publisher","first-page":"e0005893","DOI":"10.1371\/journal.pntd.0005893","volume":"11","author":"SM Yun","year":"2017","unstructured":"Yun, S. M. et al. Molecular genomic characterization of tick- and human-derived severe fever with thrombocytopenia syndrome virus isolates from South Korea. PLoS Negl. Trop. Dis. 11, e0005893 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1269_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veae054","volume":"10","author":"D Park","year":"2024","unstructured":"Park, D. et al. Deciphering the evolutionary landscape of severe fever with thrombocytopenia syndrome virus across East Asia. Virus Evol. 10, veae054 (2024).","journal-title":"Virus Evol."},{"key":"1269_CR42","doi-asserted-by":"publisher","first-page":"e1008859","DOI":"10.1371\/journal.ppat.1008859","volume":"17","author":"T Yoshikawa","year":"2021","unstructured":"Yoshikawa, T. et al. A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome. PLoS Pathog. 17, e1008859 (2021).","journal-title":"PLoS Pathog."},{"key":"1269_CR43","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3389\/fimmu.2019.02049","volume":"10","author":"S Foss","year":"2019","unstructured":"Foss, S. et al. TRIM21\u2014from intracellular immunity to therapy. Front. Immunol. 10, 2049 (2019).","journal-title":"Front. Immunol."},{"key":"1269_CR44","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.1073\/pnas.0800159105","volume":"105","author":"AH Keeble","year":"2008","unstructured":"Keeble, A. H., Khan, Z., Forster, A. & James, L. C. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc. Natl. Acad. Sci. USA 105, 6045\u20136050 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1269_CR45","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106228","volume":"40","author":"SL Caddy","year":"2021","unstructured":"Caddy, S. L. et al. Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J. 40, e106228 (2021).","journal-title":"EMBO J."},{"key":"1269_CR46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.32660","volume":"7","author":"C Dickson","year":"2018","unstructured":"Dickson, C. et al. Intracellular antibody signalling is regulated by phosphorylation of the Fc receptor TRIM21. eLife 7, e32660 (2018).","journal-title":"eLife"},{"key":"1269_CR47","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41594-021-00560-2","volume":"28","author":"J Zeng","year":"2021","unstructured":"Zeng, J. et al. Target-induced clustering activates trim-away of pathogens and proteins. Nat. Struct. Mol. Biol. 28, 278\u2013289 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1269_CR48","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jsb.2016.09.013","volume":"196","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Molecular basis for the formation of ribonucleoprotein complex of Crimean-Congo hemorrhagic fever virus. J. Struct. Biol. 196, 455\u2013465 (2016).","journal-title":"J. Struct. Biol."},{"key":"1269_CR49","doi-asserted-by":"publisher","first-page":"e38291","DOI":"10.1371\/journal.pone.0038291","volume":"7","author":"L Yu","year":"2012","unstructured":"Yu, L. et al. Critical epitopes in the nucleocapsid protein of SFTS virus recognized by a panel of SFTS patients derived human monoclonal antibodies. PLoS ONE 7, e38291 (2012).","journal-title":"PLoS ONE"},{"key":"1269_CR50","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1038\/s41467-018-05746-9","volume":"9","author":"P Song","year":"2018","unstructured":"Song, P. et al. Deficient humoral responses and disrupted B-cell immunity are associated with fatal SFTSV infection. Nat. Commun. 9, 3328 (2018).","journal-title":"Nat. Commun."},{"key":"1269_CR51","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ttbdis.2019.02.003","volume":"10","author":"G Wang","year":"2019","unstructured":"Wang, G. et al. Nucleocapsid protein-specific IgM antibody responses in the disease progression of severe fever with thrombocytopenia syndrome. Ticks Tick Borne Dis. 10, 639\u2013646 (2019).","journal-title":"Ticks Tick Borne Dis."},{"key":"1269_CR52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints12. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"1269_CR53","doi-asserted-by":"publisher","first-page":"e0008453","DOI":"10.1371\/journal.pntd.0008453","volume":"14","author":"R Chen","year":"2020","unstructured":"Chen, R. et al. Severe fever with thrombocytopenia syndrome virus infection during pregnancy in C57\/BL6 mice causes fetal damage. PLoS Negl. Trop. Dis. 14, e0008453 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1269_CR54","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1128\/JCM.00742-14","volume":"52","author":"T Yoshikawa","year":"2014","unstructured":"Yoshikawa, T. et al. Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load. J. Clin. Microbiol. 52, 3325\u20133333 (2014).","journal-title":"J. Clin. Microbiol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01269-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01269-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:11:37Z","timestamp":1760602297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01269-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1269"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01269-9","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E. has an equity interest in HDT Bio and is a co-inventor on U.S. patent application no. 62\/993,307 \u201cCompositions and methods for delivery of RNA\u201d pertaining to formulations for RNA delivery. D.W.H. has equity interest in HDT Bio. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}